TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive FDA Approves Xeloda For Breast Cancer After Failure Of Anthracycline Treatment. September 28, 2001
TCL Archive AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm May 8, 2013
TCL Archive Prevention Facility For Intramural Research Approved, Also Would Involve Academic Investigators November 1, 1991
